← Back to Influence Map
Eli Lilly and Company
OrganizationPharmaceutical company ($34.1 billion revenue in 2023) that surpassed $1 trillion market cap on GLP-1 obesity drug momentum. Maker of Mounjaro/Zepbound, insulin products, and Alzheimer's drug donanemab.
pharmaceuticals
Given
$0
Received
$0
Connections
7
Votes
0
Relationships
| Type | Connected To | Details | Source |
|---|---|---|---|
| Employed by | TIBER CREEK HEALTH STRATEGIES, INC. | Hired TIBER CREEK HEALTH STRATEGIES, INC. to lobby on Pharmaceuticals | Source |
| Employed by | TARPLIN, DOWNS & YOUNG, LLC | Hired TARPLIN, DOWNS & YOUNG, LLC to lobby on Pharmaceuticals | Source |
| Coalition with | Pharmaceutical industry | Eli Lilly is the most valuable pharmaceutical company by market cap | |
| Advocated for | Insulin Price Caps - State-Level Legislation | Eli Lilly was the first major manufacturer to voluntarily cap insulin prices at $35 | |
| Funded research at | The Heritage Foundation | Eli Lilly donor to Heritage Foundation | |
| Instrument of (target) | Eli Lilly and Company PAC | Eli Lilly PAC is the political arm of Eli Lilly and Company | |
| Worked for (target) | David Ricks | Chairman and CEO of Eli Lilly since 2017 |